Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abionyx Pharma
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
Private Company Edition: Playground’s third fund has $410m for tech, including biotech, Pivotal Life Sciences closed its second fund with $389m and Chugai will invest $200m through its new fund. Also, Tome launched with $213m, Sudo raised a $116m series B and Odyssey closed a $101m in series C.
Emerging Company Profile: The firm’s use of the CD2 co-stimulant in its T cell engager design could significantly boost anti-tumor efficacy while addressing T cell exhaustion, with a first-in-human trial planned for 2024.
The XMed conference, now NextMed Health, returns to the Hotel del Coronado with packed programming. Health care innovators will join leaders from industry, governments, organizations and academia to discuss the future of health care.
- Other Names / Subsidiaries
- Cerenis Therapeutics, Inc.
- Cerenis Therapeutics Holding SA
- Lypro Biosciences
- Iris Pharma Holding SAS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.